Cannabis genetics research comapny 22nd Century Group (NYSEAMERICSN:XXII) filed its annual report for the year ended December 31, 2019.
As quoted in the press release:
“We are pleased with the Company’s overall progress, achieving major milestones in pursuit of our strategic objectives. We are bullish on what the potential authorization of our Modified Risk Tobacco Product application will represent for the company,” said Mike Zercher, President and Chief Operating Officer of 22nd Century Group.
“In addition, we are making strides in the legal hemp/cannabis space. Through our partnership with KeyGene, we have assembled a high-quality genome sequence of two hemp/cannabis plant lines and established a new proprietary hemp/cannabis bioinformatics platform. These achievements are an example of the valuable and innovative early results that will enable the rapid breeding of novel hemp/cannabis plants which have exceptional cannabinoid profiles for medical and therapeutic use,” Zercher added.